The oral presentation, titled, “¹⁸⁶Rhenium-Nanoliposomes (¹⁸⁶RNL) for the Treatment of Leptomeningeal Metastases: Translational Insights from Clinical and Preclinical Models,” was delivered by ...
ESTERO, FL / ACCESS Newswire / May 7, 2026 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company"), ...
Looking ahead to 2030, our model projects GEV could trade at an average price of $2,188.15, with a potential range between $1,641.12 and $2,735.19. This represents a potential 107.3% return from today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results